Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002
Transaction expands Jupiter into a dual clinical-stage CNS company with an FDA-designated Novel Chemical Entity and Phase II Parkinson’s program Jupiter Neurosciences, Inc. (NASDAQ:JUNS) JUPITER, FL, UNITED STATES, July 22, 2026 /EINPresswire.com…